Cassava Sciences reported 5.12M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
Abbott USD 5.27B 834M Jun/2025
Amgen USD 3.01B 406M Jun/2025
Biogen USD 605M 24.3M Jun/2025
Cassava Sciences 5.12M 5.02M Jun/2025
Eisai JPY 42.6B 2B Jun/2025
Eli Lilly USD 2.45B 223.6M Jun/2025
Geron 1.19M 16K Jun/2025
J&J USD 7.6B 304M Jun/2025
Merck USD 2.82B 53M Jun/2025
Novartis USD 3.32B 95M Jun/2025
Pfizer USD 4.99B 2.4B Jun/2025
Roche Holding CHF 4.13B 393.5M Dec/2024